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Abstract
Evidence of reduced blood-brain barrier (BBB) integrity preceding other Alzheimer’s disease (AD) pathology provides a
strong link between cerebrovascular angiopathy and AD. However, the ‘‘Vascular hypothesis’’, holds that BBB leakiness in
AD is likely due to hypoxia and neuroinflammation leading to vascular deterioration and apoptosis. We propose an
alternative hypothesis: amyloidogenesis promotes extensive neoangiogenesis leading to increased vascular permeability
and subsequent hypervascularization in AD. Cerebrovascular integrity was characterized in Tg2576 AD model mice that
overexpress the human amyloid precursor protein (APP) containing the double missense mutations, APPsw, found in a
Swedish family, that causes early-onset AD. The expression of tight junction (TJ) proteins, occludin and ZO-1, were examined
in conjunction with markers of apoptosis and angiogenesis. In aged Tg2576 AD mice, a significant increase in the incidence
of disrupted TJs, compared to age matched wild-type littermates and young mice of both genotypes, was directly linked to
an increased microvascular density but not apoptosis, which strongly supports amyloidogenic triggered hypervascularity as
the basis for BBB disruption. Hypervascularity in human patients was corroborated in a comparison of postmortem brain
tissues from AD and controls. Our results demonstrate that amylodogenesis mediates BBB disruption and leakiness through
promoting neoangiogenesis and hypervascularity, resulting in the redistribution of TJs that maintain the barrier and thus,
provides a new paradigm for integrating vascular remodeling with the pathophysiology observed in AD. Thus the extensive
angiogenesis identified in AD brain, exhibits parallels to the neovascularity evident in the pathophysiology of other diseases
such as age-related macular degeneration.
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Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder and is
the leading cause of dementia in the elderly [1]. AD is
characterized by the presence of extracellular neuritic plaques
comprised of the amyloid-beta (abeta) peptide and intracellular
neurofibrillary tangles comprised of the tau protein [2,3]. Abeta
peptides are produced from the proteolytic cleavage of the amyloid
precursor protein (APP). The amyloid cascade hypothesis
implicates abeta as the key player in the formation of senile
plaques and neuronal death [4]. The strong link between
cerebrovascular pathology and AD was historically overlooked
since occurrences of stroke prior to the exhibition of AD-like
symptoms excluded patients from being diagnosed with AD [5].
However, recent studies have found that vascular risk factors and
neurovascular dysfunction associated with hypotension, hyperten-
sion [6,7], cholesterol levels, type II diabetes mellitus [8], smoking
[9] and oxidative stress [10] play integral roles in the pathogenesis
of AD [11]. In addition, genetic factors including the apolipopro-
tein E genotype and an associated polymorphism in the ATP-
binding cassette A1 lipid transporter indicate a direct link between
AD and vascular disease [12]. Furthermore, approximately 90%
of AD patients have cerebrovascular amyloid angiopathy (CAA),
consisting of abeta in small arteries, arterioles and capillaries [13].
CAA is also present in 50% of the population over the age of 90
years [13]. Vascular accumulation of abeta species 1–42 and abeta
species 1–40 in AD is becoming a well-documented risk factor for
cerebral hemorrhage, atherosclerosis and arteriosclerosis
[14,15,16]. CAA involves the deposition of abeta within the small
blood vessels of the brain and is found within the walls of the
leptomeninges and parenchymal arteries, arterioles and capillaries
[17,18]. Thickening of arteriole walls and formation of microan-
eurysms occur concurrently in CAA. CAA is associated with
degeneration of smooth muscle cells, ischemic white matter
damage, fibrinoid necrosis and dementia [19]. Additionally, the
E22Q (Dutch), and E22G (Arctic) mutants produce vasculotropic
variants peptides of abeta 1–40 that contribute distinct hereditary
phenotypes of cerebral amyloid angiopathy, manifesting varying
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microvessel remodeling and angiogenesis [20] that differentially
activate mitochondrial apoptotic pathways [21].
Blood brain barrier (BBB) dysfunction was initially identified in
animal models of AD [22] and was later confirmed as a
prominent, though unexplained, clinical feature of AD in patients
[23]. The origin of BBB dysfunction during AD is not known, but
APP expression leading to the generation of abeta may be directly
involved in this process as BBB leakiness has been demonstrated in
a number of AD transgenic animals models in which forms of APP
are overexpressed, including the Tg2576 that overexpresses the
human APP695 containing the double missense Swedish muta-
tions (K670N/M671L) that causes a form of early-onset AD
[22,24,25,26]. We have previously demonstrated that BBB
integrity is compromised in this mouse model as early as 4
months of age; long before other disease pathology occur, such as
consolidated amyloid plaques [22]. These and other studies that
assessed BBB integrity by examining serum protein leakage and
dyes extravasation have shown that BBB disruption is subtle,
transient, and consistent in older mice [22,24,25,26], however the
exact pathophysiology that leads to BBB leakiness is still unclear.
In addition, we have also shown that vaccination with abeta can
reverse BBB pathology [26]. Furthermore, our animal studies are
complimented by magnetic resonance imaging (MRI) and related
in vivo imaging studies [23] that show BBB permeability is
increased in humans affected with AD. Overall, our previous data
and those from other studies are consistent with the current
‘‘vascular hypothesis’’ in which vascular damage is caused by
reduced blood perfusion of the brain leading to hypoxia, and BBB
dysfunction and subsequent neurodegenerative changes such as
the accumulation of abeta [27,28], neuroinflammation [29], and
the eventually breakdown of the neurovascular unit [30] resulting
in vascular death. Under hypoxia, hypoxia-inducible factors
initiate angiogenesis through the upregulation of angiogenic
factors, such as vascular endothelial growth factor (VEGF).
Angiogenesis, in this model, would be required to ensure tissue
regeneration but would likely be limited to replacing the damaged
tissues and ensuring oxygenation of brain tissues. The ‘‘vascular
hypothesis’’ is becoming an increasingly important area of clinical
and scientific exploration; however, it is interesting to consider
alternative explanations that are consistent with the existing body
of evidence.
The BBB refers to the extensive network of capillary blood
vessels, comprised of highly specialized endothelial cells, which
compartmentalize the brain from the peripheral blood. The
physical seal of the BBB is maintained by several different inter-
endothelial tight junctional complexes (reviewed by [31,32])
comprised of a variety of plasma membrane spanning proteins
(like occludin), scaffold cytoplasmic proteins (like ZO-1) and the
actin cytoskeleton. Therefore, it is possible that amyloidogenesis
influences BBB integrity in AD at the level of the tight junction
(TJ) proteins that maintain the barrier. Here we directly address
the hypotheses that mechanisms that influence the BBB disruption
are due to vascular cell death caused by apoptosis, consistent with
the ‘‘vascular hypothesis’’ of AD or endothelial cell proliferation
during angiogenesis resulting in hypervascularity in AD.
Our objective was to characterize the relationship between
amyloidogenesis and BBB integrity through changes in TJ
morphology in the Tg2576 AD mouse and thereby, identify a
mechanism that can explain BBB disruption in AD. We report that
the Tg2576 AD mice exhibit no apparent vascular apoptosis but
have significant TJ disruption, which is directly related to
neoangiogenesis leading to a significant increase in vascular density
in AD brain. Establishing hypervascularization as a mechanistic
explanation for amyloid associated TJ pathology provides new
modalities for therapeutic intervention that target the restoration of
the BBB by modulating angiogenesis, thereby possibly prevent AD
onset and potentially repairing damage in the AD brain.
Materials and Methods
Ethics Statement
All animal procedures were conducted with approval by the
University of British Columbia Animal Care Committee under the
direction of the Canadian Council for Animal Care.
Mice
Tg2576 transgenic (Tg/+) mice were used in this study. These
mice express human APP695 containing the Swedish missense
mutations (K670N/M671L) or APPsw [33], under control of the
hamster prion protein promoter (Taconic). Mice were maintained
on mixed C57Bl6/SJL background by mating heterozygous
Tg2576 males to C57Bl6/SJL F1 females. Wild-type (+/+)
littermates were used as controls. Aged mice were 18 to 24
months of age while young mice were five months of age. Mice
were fed standard lab chow and water ad libitum and kept under a
12 hour light/dark cycle.
Classification of Human Brain Tissues
Well-characterized tissue reference standards of postmortem
medial cortical and hippocampal brain tissues were obtained from
the Kinsmen Laboratory Brain Bank at the University of British
Columbia (Vancouver, BC, Canada). Reference standards of
brains from no disease (ND) and from AD patients were used.
Classification of clinical and pathological histories of the respective
patients were as described in [34].
Tissue preparation
Mice were terminally anesthetized with Avertin (0.0 2 mL/1 g).
Brains were rapidly excised, olfactory bulbs removed and post-
fixed in 4% paraformaldehyde for four days at 4uC. The brains
were then imbedded in paraffin and sectioned serially at 5 mm.
Paraffin embedding, sectioning, and dewaxing were performed by
Wax-it Histology Services Inc. (Vancouver, BC, Canada). For
immunoblotting, brains were rapidly excised and the hippocampus
and neocortex was isolated from both brain hemispheres using
methods demonstrated by Hagihara et al. [35].
Immunostaining
Dewaxed paraffin mice brain sections underwent antigen
retrieval using a conventional stovetop pressure cooker using
20 mM Tris with 0.7 mM EDTA buffer (pH 9.0) at full steam for
2 minutes. Cooled slides were then incubated in blocking buffer
(25% normal goat serum; 3% BSA; 0.3% Triton X-100, Sigma)
for 1 hour at room temperature. Primary antibodies used included
rabbit anti-ZO-1 (1:200, Invitrogen), mouse anti-ZO-1 (1:200,
Invitrogen), rabbit anti-occludin (1:200, Invitrogen), rabbit anti-
activated caspase-3 (1:1000, Imgenex), and mouse anti-human
CD105 (1:20, DAKO). Primary antibody staining was performed
overnight at 4uC in staining buffer (10% normal goat serum; 3%
BSA; 0.3% Triton X-100). Normal donkey serum was used when
staining with goat primary antibodies. Secondary antibodies used
were complimentary to the species of the primary conjugated with
either Alexa Fluor dyes 488 or 568 (1:500, Invitrogen). Secondary
antibody staining was performed at room temperature for 1 hour
in staining buffer. TOTO-3 (1:10000, Invitrogen) was used for
nuclear counterstaining. Sections were washed in PBS with 0.1%
Tween-20 (Sigma) three times for 5 minutes each between staining
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(Southern Biotech) and allowed to air dry in the dark overnight.
Human brain tissues were stained using methods described by
[34]. Briefly, free-floating 30 mm thick sections were immunola-
belled with an anti-lamininprimaryantibody(1:100, rabbit, Sigma).
Sections were then treated with the appropriate biotinylated
secondary antibodies (1:1000; DAKO) for 1 hour at room
temperature, followed by incubation in avidin-biotinylated horse-
radish peroxidase complex (1:1000; ABC Elite, Vector Labs).
Peroxidase labeling was visualized by incubation in 0.01% 3,3-
diaminobenzidine (DAB; Sigma) solution. When a dark purple/
black color developed, sections were washed, mounted on glass
slides, air-dried and coverslipped with Entellan (EMD Biosciences).
Confocal and quantitative analysis of tight junction
morphology
Brain sections were analyzed from paraffin blocks from every
fifth section. Images, taken on a Zeiss LSM510 Meta (Zeiss,
Germany), were acquired with 16 slices, averaged four times,
through the Z-plane using a 406/1.3 oil-immersion Plan-Neoflaur
objective. The composite projected image was imported into
Adobe Photoshop at 600 dpi and optimized for contrast and
brightness. Quantitative analysis of tight junction morphology was
analyzed according to the methodology developed by Plumb et al.
[36]. Confocal data sets represented approximately 100 cerebral
blood vessels from both young and aged Tg2576 and littermate
controls in the frontal cortex and hippocampus. Individual vessels
were scored as either normal (1) or abnormal (0) for ZO-1
expression. Normal ZO-1 expression was judged as strong,
continuous, intense and linear staining. In contrast, abnormal
ZO-1 expression was judged as weak, punctate and/or discontin-
uous staining. Abnormal ZO-1 blood vessel expression was
compared to normal blood vessels found in normal control or in
normal vessels in diseased brains. To minimize the recording of
incomplete or undulating vessels as abnormal due to observed
‘‘gaps’’ in ZO-1 staining, evidence of vessel continuity was sought
in the images. For example, the presence of stained nuclei (with
TOTO-3) or punctate or diffuse ZO-1 remnants was used to
localize the position of abnormal gaps along the vessel tract. The
incidence of tight junction disruption was defined as the average
percentage of blood vessels in a given region of brain that
displayed abnormal tight junction morphology.
Microvessel density quantification in Mouse Tissues
Microvessel density (MVD) was quantified by confocal micros-
copy using the methods developed by Guo et al. [37] with minor
modifications. Using CD105 as a marker of angiogenic cerebro-
vasculature [38], images of optimal fluorescent intensity were
acquired and analyzed using the Zeiss LSM510 Meta software.
Areas within the brain section containing high density (‘‘hotspots’’)
[39] CD105 staining were imaged using the 206/0.45 N-
Achroplan objective using the confocal imaging parameters
mentioned previously. The total fluorescence area (TFA) in mm
2
was integrated above background, by the software, for each
hotspot. The average TFA from four different hotspots per mouse
was quantified. The TFA was used as a numerical representation
of the total microvessels stained by the CD105 antibody. The
MVD of the imaged field was expressed as a ratio of the TFA to
the total area of the image.
Microvessel density quantification in Human Tissues
MVD was quantified using the hotspot method, similar to how
the MVD in the mice were quantified. Briefly, areas within a brain
section containing high density (‘‘hotspots’’) [13] laminin staining
were imaged using a Olympus LCPlanFL 206/0.40 Objective on
a Zeiss Axioplan-2 light microscope equipped with a DVC camera
(Diagnostic Instruments). MVD quantification was performed
using ImageJ (Rasband, W.S., ImageJ v1.44p, U. S. National
Institutes of Health, Bethesda, Maryland, USA, http://rsb.info.
nih.gov/ij/, 1997–2011). A background threshold level was
initially determined from an 8-bit grey scale, derived from an
original black and white image, in control slides processed without
primary antibody. The percentage of pixels having a staining
intensity greater than the corresponding threshold was then used
to integrate the percentage area occupied by laminin staining for
each hotspot. The average percentage area occupied by laminin
staining from four different hotspots per brain region per patient
was quantified. The MVD of the imaged field was expressed as a
percent area occupied by the laminin staining to the total area of
the image.
Quantitative western blot analysis
Isolated neocortex and hippocampal tissues were homogenized
in 1% NP-40 lysis buffer (20 mM Tris-base (pH 8.8), 2 mM
EDTA, 150 mM NaCl, 1% NP-40 with protease inhibitors
(Roche)) using a QIAGEN TissueLyser II set at 19 Hz for
20 minutes. To shear genomic DNA, homogenized samples were
passed ten times through a 21-gauge needle then incubated on ice
for 30 minutes. The homogenate was centrifuged at 4uCa t
140006g for 30 minutes. Protein concentrations from the
supernatants were determined by BCA assay (Pierce) and samples
were adjusted to final concentration of 30 mg per lane. Proteins
were resolved in 10% SDS-PAGE gels according to standard
practices [40]. Immunoblotting was performed on nitrocellulose
membranes (Pall) using rabbit anti-occludin (1:1000, Invitrogen),
mouse anti-human CD105 (1:1000, DAKO) and mouse anti-beta
actin (1:1000, Santa Cruz). Alexa Fluor 680-conjugated anti-rabbit
IgG (Invitrogen) and IRDye800 conjugated anti-mouse IgG
(Rockland) were used as secondary antibodies. All antibody
dilutions were made in milk protein solutions. Signal intensities
were analyzed by using the Odyssey infrared image system
(LICOR).
Statistical analysis
All experiments were performed at least three times in triplicate.
Statistical comparisons of data between aged and young Tg2576
AD mice and wild-type control littermates were performed with
either Student’s t-test or 2-way ANOVA for unmatched values
with Bonferroni post-tests. All statistical analyses were performed
using GraphPad Prism (v5.01 for Windows, GraphPad Software,
San Diego California USA, www.graphpad.com). p-values less
than 0.05 were considered significant. Values are expressed as
mean 6 SEM.
Results
Tg2576 mice have a higher incidence of abnormal
cerebrovascular tight junction morphology
To assess changes in TJ morphology we examined the staining
patterns of occludin and ZO-1, both well-established TJ markers,
by confocal microscopy. TJ morphology was characterized in
several brain regions including the neocortex, hippocampus and
choroid plexus of wild-type and Tg2576 mice. Nearly all the
observed blood vessels were sectioned longitudinally. Transverse
blood vessels were rare. Strong, continuous and linear staining
patterns of occludin and ZO-1 within the cerebrovasculature were
considered normal, which was indistinguishable in both the cortex
Tight Junction Dysfunction in Alzheimer’s Disease
PLoS ONE | www.plosone.org 3 August 2011 | Volume 6 | Issue 8 | e23789or hippocampus regardless of age or genotype [[Figure 1: A, C,
E and G]]. The faint outline of the vessel track, enhanced by
nuclear counterstaining, allowed junctional abnormalities to be
easily spotted. Compared to controls, Tg2576 mice exhibited a
higher incidence of punctate staining of occludin [[Figure 1: B
and F]] and ZO-1 [[Figure 1: D and H]] in the neocortex and
hippocampus, respectively. The choroid plexus, a region of the
brain not affected in AD, exhibited normal TJ patterns for both
occludin and ZO-1 in all mice (data not shown).
We then quantified the TJ disruption by calculating the average
percentage of blood vessels displaying abnormal morphology. The
neocortex of aged Tg2576 mice showed a significant increase in
TJ disruption (30.5061.94%; ***p,0.001, 2-way ANOVA)
compared to wild-type littermates (which averaged 10%)
[[Figure 2: A]]. There was also a significant difference in the
incidence of TJ disruption between aged Tg2576 and young,
Tg2576 mice (*p,0.05, 2-way ANOVA) [[Figure 2: A]].
Similar results were seen in the hippocampus. Aged Tg2576
mice (24.7562.32%; ***p,0.001, 2-way ANOVA) showed a
significant increase in the incidence of TJ disruption compared to
wild-type littermates (averaging 10%) [[Figure 2: C]]. A
significant increase in the incidence of TJ disruption was seen in
aged Tg2576 mice compared to young Tg2576 mice (*p,0.05, 2-
way ANOVA) [[Figure 2: C]]. The amount of TJ disruption in
young mice, in both the cortex and hippocampus, of both
genotypes averaged approximately 10% and was not significant.
Occludin protein levels were examined by western blot in the
neocortex and hippocampus of aged Tg2576 mice. In the cortex,
the ratio of occludin to b-actin was reduced by nearly half
[[Figure 2: B]] in the transgenic mice (3.7860.49) compared to
the wild-type (6.8160.80, **p=0.0072, t-test). The hippocampus
exhibited a similar reduction in the ratio of occludin to b-actin in
the aged Tg2576 mice (5.8960.76) compared to the wild-type
(10.3161.15, **p=0.0076, t-test) [[Figure 2: D]].
Aged Tg2576 brains have limited apoptotic and
increased angiogenic cerebral vascular signals
Apoptosis and angiogenesis were explored as possible mecha-
nisms to explain the observed brain vascular TJ abnormalities in
the aged Tg2576 mice. We used activated caspase-3 as a marker of
apoptosis [[Figure 3: C–D]]. In all examined sections, there was
no activated caspase-3 immunoreactivity in endothelial cells.
Activated caspase-3 staining was noted in other cell types and had
a filamentous-like morphology. In young and aged wild-type mice,
there was very limited activated caspase-3 staining within the
neocortex [[Figure 3: C]]. Blood vessels in the cortex and
hippocampus that did exhibit TJ abnormalities, [[Figure 3: D]],
had a filamentous-like staining morphology that was directly
adjacent to or overlapped with blood vessels [[Figure 3: D
(white arrows)]]. All mice had hippocampal staining of activated
caspase-3 in the CA1, CA2, CA3 and DG regions to various
degrees. Young Tg2576 and wild-type (both young and aged) had
significantly higher activated caspase-3 staining densities within
the hippocampus compared the cortex. The overall density of
caspase-3 hippocampal staining in young Tg2576 and wild-type
(all ages) mice was noted to be lower than aged Tg2576 mice.
However, aged Tg2576 mice had significant activated caspase-3
staining within the both the neocortex and hippocampus that
tended to center around probable plaque locations.
To assess for angiogenesis we used CD105, a well establish
endothelial marker [41]. CD105 stained all vessels uniformly,
regardless of age and genotype. However, a higher proportion of
blood vessels were stained with CD105 in aged Tg2576 compared
to age-matched wild-type littermates and young mice of both
genotypes [[Figure 3: B]].
Aged Tg2576 mice have increased microvascular density
It was noted earlier that a higher proportion of blood vessels
were stained with CD105 in aged Tg2576mice. The microvascular
density (MVD) was quantified in the brains of young and aged
Tg2576 mice and age-matched wild-type littermates by CD105
staining. The MVD was defined as a ratio of the TFA to the total
area of an imaged field and was used as a surrogate measure of
angiogenesis. Aged Tg2576 mice had a significantly higher MVD
compared to wild-type. The average MVD in aged Tg2576 mice
(0.445360.0146; ***p,0.001, 2-way ANOVA) was over double
that of wild-type (0.188260.0010) [[Figure 4: A]]. When
compared to young Tg2576 mice, the MVD in aged Tg2576
was over 1.5 times (*p,0.05, 2-way ANOVA). Young Tg2576
mice had a trend towards a higher average MVD
(0.267460.0161) but the differences were not significantly
different compared to wild-type (0.232160.0110) [[Figure 4: A]].
CD105 protein expression levels were quantified by western blot
in both the neocortex and hippocampus of aged Tg2576 and wild-
type mice. In the cortex, the ratio of CD105 to b-actin was nearly
double [[Figure 4: B]] in the Tg2576 mice (4.5760.27)
compared to that of the wild-type (2.5260.27, ***p,0.001, t-
test). The hippocampus exhibited a similar increase in the ratio of
Figure 1. Tg2576 AD mice have cerebral tight junction
pathology. Representative confocal micrographs of cerebral blood
vessels from aged Tg2576 and wild-type mice immunolabeled for either
occludin or ZO-1 (red) and counterstained for DNA (blue) with TOTO-3.
Blood vessels, imaged in the neocortex and hippocampus, which
exhibited strong, continuous and linear occludin (A and C) or ZO-1 (E
and G) expression were considered normal, as demonstrated in the
wild-type. Abnormal occludin (B and F) and ZO-1 (D and H) staining
displayed punctate (white arrowheads), discontinuous or interrupted
(hollow white arrows), as seen in the Tg2576 cerebrovasculature.
Results are representative from three mice per group from three
separate experiments. Scale bar represents 20 mm.
doi:10.1371/journal.pone.0023789.g001
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to the wild-type (3.5360.46, *p,0.05, t-test) [[Figure 4: C]].
In a preliminary examination of human tissues, quantifying the
amount of laminin staining in the brains of no disease (ND) and
AD patients was conducted in carefully validated cases from the
Kinsmen Laboratory Brain Bank at University of British
Columbia. These samples were used as reference standards of
postmortem medial cortical and hippocampal brain tissues [34] to
provide support that increased cerebral vascular density also
extends from animal models of AD into clinical disease in humans.
In the cortex of the AD reference standard, the average MVD by
percent area was nearly double (12.2361.28%, *p,0.05, t-test)
compared to the ND patient (7.2561.25%) [[Figure 4: D]].
Similarly, the hippocampus of the AD reference displayed a
doubling in the average MVD (11.3560.60%, ***p,0.001, t-test)
compared to the ND reference (7.1060.23%) [[Figure 4: E]].
The extent of the increased cortical cerebral vascular density from
laminin staining in the AD patient [[Figure 4: G]] can be visually
seen in the representative images compared to the ND patient
control [[Figure 4: F]. Hippocampal tissue displayed similar
staining patterns in the AD and ND patients (data not shown).
Additional work is needed to further extend these observations in
populations of AD patients and controls.
Discussion
Reduced BBB integrity precedes other AD neuropathology such
as amyloid plaques. However, the current dogma holds that BBB
Figure 2. Aged Tg2576 Mice have reduced tight function expression. The expression of occludin or ZO-1 were compared quantitatively
between wild-type and Tg2576 mice in the neocortex (A and B) and hippocampus (C and D). (A) The percentage of cortical cerebral blood vessels
with abnormal ZO-1 expression patterns was significantly higher in the aged Tg2576 mice compared to age-matched wild-type (***p,0.001). The
incidence of ZO-1 disruption was also significantly higher in aged Tg2576 mice compared to young Tg2576 (Young wild-type, n=4; Young Tg2576,
n=3; aged wild-type, n=5; aged Tg2576, n=4; *p,0.05) in the cortex. (B) Aged Tg2576 mice had significantly reduced occludin protein levels in the
cortex compared to age-matched wild-type (n=7, **p=0.0072). (C) The percentage of hippocampal cerebral blood vessels with abnormal ZO-1
expression patterns was significantly higher in the aged Tg2576 mice compared to age-matched wild-type (***p,0.001). Similarly, the incidence of
ZO-1 disruption was also significantly higher in aged Tg2576 mice compared to young Tg2576 (Young wild-type, n=4; Young Tg2576, n=3; aged
wild-type, n=5; aged Tg2576, n=4; *p,0.05) in the hippocampus. (D) Aged Tg2576 mice had significantly reduced occludin protein levels in the
hippocampus compared to age-matched wild-type (n=7, **p=0.0076). Values represent mean 6 SEM.
doi:10.1371/journal.pone.0023789.g002
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apoptosis resulting from brain hypoxia. The goal of this study
was to test the ‘‘Vascular hypothesis’’ of AD [30] that would
require evidence of cerebrovascular damage and apoptosis, or the
alternative hypothesis, that amyloidogenesis leads directly to
angiogenesis and hypervascularization that underlie increased
vascular permeability in AD. We have previously established by
quantification using the Evans Blue dye method, that the BBB is
compromised in the Tg2576 AD model mouse that express a
human APP695 transgene containing the Swedish missense
mutations (K670N/M671L) or APPsw [33], under control of the
hamster prion protein promoter. We also demonstrated that the
breakdown of the BBB can be rescued by immunization with abeta
[22,26]. In the present study, the integrity of the BBB was assessed
by examining TJ morphology in Tg2576 AD mice that express the
human APP containing the double missense mutations, found in a
Swedish family, that causes early-onset AD. Two separate age
groups of mice were examined: five months old (prior to disease
onset) and aged 18+ months old (well-after disease onset). Aged
Tg2576 mice were found to have significantly abnormal TJ
expression, compared to controls, which correlated with increased
angiogenesis and hypervascularization. Taken together, the
expression of APPsw influences angiogenesis that appears to cause
BBB disruption in Tg2576 mice at the level of TJs. This study is
believed to be the first comprehensive examination of TJ related
BBB dysfunction in AD and is important in the characterization
the pathophysiology of AD brain.
Our data do not support the existing ‘‘vascular hypothesis’’ of
AD and rather support the concept that amyloidogenesis leads
directly to angiogenesis rather than through a model requiring
hypoxia, vascular damage and subsequent vascular repair. During
amyloidogenesis, abeta peptides arise by successive cleavage of
unprocessed APP by beta-and gamma-secretases [42,43,44,
45,46,47] and recently, it has come into question whether the
large aggregated extracellular abeta plaques, a hallmark of AD
pathology, directly cause the neurodegenerative effects in AD. It is
emerging that the smaller, more toxic, soluble abeta oligomers
may directly initiate disease (reviewed by [48]). It has been
suggested that the presence of these toxic oligomers could
negatively influence endothelial survival and TJ expression.
However, our data is consistent with the possiblity that
vasculotropic peptides of abeta generated during amyloidogenesis
contribute to cerebral amyloid angiopathy and effect microvessel
remodeling and angiogenesis [20,21]. Several lines of in vitro
evidence have explored endothelial dysfunction by abeta. Marco et
al. [49] demonstrated that abeta 1–42 stimulated endothelial
cultures induced aberrant expression of TJ proteins including
claudins, occludins and ZO-1. Gonzalez et al. [50] demonstrated
that smaller abeta 1–40 aggregates induced endothelial cell
permeability and the relocalization of ZO-1 to the cytoplasm. In
these studies, abeta induced reactive oxygen species (ROS) was
ruled out as a potential cause of BBB leakiness because the
presence of ROS detoxifying enzymes did not influence abeta
induced damage [51]. However, the reorganization of cytoskeletal
proteins was believed to directly influence BBB integrity [51].
Another potential contributor to vascular remodelling in AD is
APP itself that has been reported to possess weak ferroxidase
activity [52]. Impairment of APP ferroxidase activity in AD could
result in ferrous iron overload and result in the formation of
superoxide anions and hydroxyl radicals that could result in
damage of brain tissues. ROS from other sources including
microglial activation, inflammation, from serum leakage, could
also effect BBB integrity [53]. However, if this were the case, we
would likely be evidence of significant vascular apoptosis in the
brains of Tg2576 mice and we can presently find no indication of
this.
Another potential mediator of cerebrovascular disruption in
AD is a highly toxic dodecameric 56 kDa abeta oligomer,
referred to as ‘‘abeta*56’’ that has been directly implicated in
memory loss in Tg2576 mice [54]. This oligomer emerges at
about six months of age in the Tg2576 mice, when memory
deficits first become apparent, but is absent in younger mice [54].
In the present study, five-month old mice had a trend towards
increased abnormal vascular TJs. However, Tg2576 mice begin
showing a loss of BBB integrity as early as four months of age
[22]. During this time, a build-up of smaller less toxic oligomers
could begin negatively influencing BBB integrity in this mouse.
By six months of age, it is hypothesized that the toxic presence of
abeta*56 initiates a cascade of the pathological events associated
with the Tg2576 mouse. Although, between the ages of six to 13
months, the relative levels of abeta*56 remain constant in the
Tg2576 mice [54]. During this time the eventual accumulation of
plaques and dystrophic neurons is enough to cause further
pathological damage in this mouse. This could explain the
dramatic presence of abnormal cerebral vascular TJ expression in
the aged Tg2576 mice, but again however, this mechanism would
Figure 3. Angiogenesis not apoptosis induces alterations in
tight junction immunoreactivity in Tg2576 mice. Representative
confocal micrographs of TJs (ZO-1), double stained for markers of
angiogenesis or apoptosis in aged wild-type and Tg2576 mice. All
vessels stained for CD105 regardless of the TJ expression pattern. White
arrowheads point to regions of TJ abnormality in the vasculature.
Double staining of blood vessels with ZO-1 (red) and CD105 (green) in
wild-type (A). and Tg2576 (B) neocortex. Double staining of vessels with
ZO-1 (red) and caspase 3 (green) in wild-type (C) and Tg2576 (D)
neocortex. Caspase-3 staining did not colocalize with ZO-1 staining
indicating an absence of apoptosis in the vasculature. Results are
representative of three separate experiments of three mice per group of
brain tissues examined. Scale bar represents 20 mm.
doi:10.1371/journal.pone.0023789.g003
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PLoS ONE | www.plosone.org 6 August 2011 | Volume 6 | Issue 8 | e23789Figure 4. Microvascular Density is increased in Aged Tg2576 and in Human patients with AD. The MVD, by CD105 staining, in the
cerebrovasculature and CD105 protein expression were quantified in aged and young Tg2576 and wild-type. (A) Aged Tg2576 mice had a
significantly higher MVD compared to age-matched wild-type (***p,0.001). Aged Tg2576 were had a significantly higher MVD compared to young
Tg2576 (Aged wild-type, n=5; aged Tg2576, n=4; young wild-type, n=4; young Tg2576, n=3; *p,0.05). Although not significant, young Tg2576
mice trended to a higher average MVD compared to wild-type. (B) Aged Tg2576 mice had a significantly increased CD105 protein levels in the cortex
compared to age-matched wild-type (wild-type, n=5; Tg2576, n=6; ***p,0.001). (C) Aged Tg2576 mice had a significantly increased CD105 protein
levels in the hippocampus compared to age-matched wild-type (n=7, *p,0.05). (D) The cortex of the AD patient had a significantly increased MVD,
as measured by % area occupied by laminin staining, compared to the ND patient (n=4, *p,0.05). (E) The hippocampus of the AD patient had a
significantly increased MVD, as measured by % area occupied by laminin staining, compared to the ND patient (n=4, ***p,0.001). Representative
images of immunohistochemical staining for laminin in the cortex of the ND patient (F) and the AD patient (G). Scale bar represents 95 mm. Values
represent mean 6 SEM.
doi:10.1371/journal.pone.0023789.g004
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not only wide-spread angiogenesis but hypervascuarity in the
absence of endothelial apoptosis. In the context of the present
study, it will be interesting to determine if abeta*56 exhibits pro-
angiogenic activity suggested by our studies rather than
displaying toxic effects towards cerebrovasculature.
In contrast to the studies summarized above that contemplate
amyloidogenesis resulting in endothelial damage, our study using
an antibody against activated caspase-3 failed to detect endothelial
apoptotic events. However, young (5 months of age) and aged (18–
24 months of age) Tg2576 and corresponding wild-type mice
exhibited active caspase-3 expression with non-endothelial staining
predominately within the hippocampus. These data are consistent
with the absence of wide-spread endothelial cell death. Although,
apoptotic endothelial cells were not observed in this study, in vitro
evidence does suggest that abeta, especially mutations pertaining
to the Dutch mutant, have been shown to induce apoptosis in
cultured endothelial cells [21,55,56]. Clearly, in vivo evidence from
clinical studies of AD and in other animal models of AD, is needed
in order definitely clarify if abeta induced endothelial apoptosis
takes place that we cannot detect or whether the absence of
endothelial apoptosis observed with the methods used in this study
are validated by other approaches.
Angiogenesis was also examined as another potential mecha-
nism for explaining TJ disruption in cerebrovascular endotheli-
um. There are several lines of evidence that suggest angiogenesis
occurs during AD. First, neuroinflammation is a pathological
feature of AD [57] and is associated with the increase in
cytokines, like IL-1b, that are capable of inducing angiogenesis
[58]. The pro-angiogenic growth factor VEGF is also induced by
these cytokines [59] and is elevated in AD patients [60]. VEGF
directly stimulates endothelial proliferation [61]. Abeta peptides
themselves have also been shown to have angiogenic properties
[62]. Here, CD105 was used to examine angiogenesis in cerebral
blood vessels labeled with the TJ markers. The CD105 expression
was not able to distinguish vessels with TJ abnormalities from
those without [41], however, the apparent pan-endothelial
staining of CD105 was extremely useful as it allowed the
quantitation of the density of CD105 staining and thus the
microvascular density (MVD), in the entire brain. The MVD was
used as a surrogate marker for the amount of angiogenesis
present within a given area of tissue section. The greater the
vascular density, the more angiogenesis is believed to have
occurred. Measuring the MVD is not without limitations, which
include a lack of standardization and reliance on the operator to
minimize bias leading to the loss of objectiveness [63].
Nonetheless, aged Tg2576 mice had nearly double the MVD
compared to age-matched wild-type mice. Young Tg2576 mice
exhibited no significant differences in MVD but had a trend
towards an increase in MVD compared to the controls.
Angiogenesis in the Tg2576 mouse is controversial. Paris et al
[64] noted the Tg2576 mouse to have limited angiogenesis. The
pan endothelial marker PECAM was used to examine angiogen-
esis in mice up to 17 months of age. Although there is no
consensus in the literature as to which is the ‘‘best’’ marker for
studying angiogenesis in the brain, PECAM is not favoured as an
angiogenic marker as compared to CD105 [65] since PECAM is
not limited to pan-endothelial expression as plasma and
inflammatory cells are typically immunolabeled also [66].
CD105 on the other hand has been shown to consistently react
with endothelials cells [65], especially those undergoing angiogen-
esis, and does not react with stromal or inflammatory cells [67,68].
The data presented herein, demonstrates that an increased
CD105-related MVD does indicate that angiogenesis and TJ
abnormalities are related in the Tg2576 mouse. Pro-angiogenic
signals have been detected in the Tg2576 mouse. Elevated VEGF
in the cortical tissue of 20 month old Tg2576 mice [69] supports
the hypothesis that angiogenesis occurs in this AD model. Finally,
increased expression of activation markers associated with
angiogenesis of cerebral vasculature has been observed in human
AD brains: laminin or von Willerbrand factor expression [34];
integrin aV-b3 expression [70]; and in the APP23 AD mouse
model beta3-integrin subunit expression [59]. The conclusions
from these studies teach that angiogenesis is exclusively a result of
vascular remodeling that takes place as a result of reduced blood
perfusion of the brain resulting in hypoxia. Furthermore, BBB
dysfunction leads to neurodegenerative changes including accu-
mulation of Ab [27,28], neuroinflammation [29] and ensuing
breakdown of the neurovascular unit [30] leading to vascular
damage and death. We cannot find evidence of cerebral vascular
death in the Tg2576 mouse and in contrast, we provide evidence
of a extensive neovascularization in the Tg2576 mouse. Further-
more, in a preliminary examination of well-characterized normal
and AD reference standards of postmortem medial cortical and
hippocampal brain tissues also exhibit significant hypervascularity
in AD, far beyond that present in a normal human brain
[[Figure 4: F–G]].
In many ways, the hypervascularity we report in AD appears to
parallel Choroidal neovascularization (CNV) also referred to as
the wet form of age-related macular degeneration [71]. It may be
wise, therefore, to consider the wider hypothesis that hypervascu-
larization is a cause, not a symptom, of senile dementias, including
AD, and perhaps contributes to the pathophysiology of other
neurological diseases as well. Therapeutic strategies for AD are
desperately needed. It remains to be demonstrated whether
modulating AD-related neovascularization will provide a novel
treatment for AD. However, given the similarities between the wet
form of AMG and AD, future studies can examine this possibility
and whether these diseases share biomarkers that can be utilized as
aids to diagnose disease, to discover new drugs and to monitor the
effectiveness of therapies. Furthermore, vascular related defects
have been noted in one of the more advanced experimental
therapies for AD that involves mounting an immune response to
abeta. Modulating the effects of amyloidogenic-related angiogen-
esis in relation to anti-abeta immunotherapy could provide novel
insights into enhancing current therapeutic approaches.
In summary, this is the first study that indicates that
amyloidogenesis leading to AD, regulates and promotes neoan-
giogenesis that results in extensive disruption of TJ’s during
vascular growth and proliferation of the BBB. This phenomenon is
increasingly manifested with age and with disease severity and
results in substantial hypervascularization that is clearly evident in
both murine and human forms of AD. Thus, these data support
the model that TJ disruption results from increased vascular
permeability that takes place during extreme neovascularization in
AD, likely triggered by production of APP, abeta or perhaps
abeta*56 during amyloidogenesis. These pathophysiological fea-
tures are profound and severe, appear early in disease develop-
ment, and may rival neurofibrillary tangles, dystrophic neurons
and amyloid plaques as characteristic hallmarks of AD.
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